How To Select The Right Fill-Finish CDMO For Phase I–II

Selecting the right fill‑finish partner for Phase I–II can be challenging, as emerging programs often fall between the capabilities of large commercial manufacturers and small boutique providers. Early clinical development requires careful handling of limited API, small batch sizes, evolving formulations, rapid tech transfers, and intensive documentation—all areas where flexibility and technical depth are equally important. Large CDMOs, built for high‑volume commercial production, may struggle to provide the scheduling priority, adaptability, and small‑scale support early‑phase teams need. Smaller operations may offer speed, but often lack advanced contamination‑control systems, isolator technology, integrated microbiology support, and regulatory infrastructure.

Mid‑sized CDMOs are increasingly well‑suited for this stage, offering both manual and automated aseptic filling, Annex‑aligned contamination‑control strategies, flexible batch volumes, integrated analytical services, and the ability to support transitions from Phase I to Phase II without facility changes. This model helps emerging biotech teams maintain continuity, manage risk, and build a scalable foundation for future development.